• Trichostatin A (TSA): Epigenetic Precision in Organoid and C

  2026-05-27

  Explore how Trichostatin A (TSA) enables precise epigenetic modulation in advanced organoid systems and cancer models. This article reveals new assay strategies and practical insights, building on recent breakthroughs in self-renewal and differentiation control.

• Applied Use of (-)-Blebbistatin in Non-Muscle Myosin II Stud

  2026-05-27

  (-)-Blebbistatin from APExBIO enables precise, reversible inhibition of non-muscle myosin II, empowering researchers to dissect cytoskeletal and mechanotransduction processes with minimal off-target effects. Advanced workflow integration and troubleshooting tips ensure robust results in cell adhesion, migration, and force-transduction studies.

• Copper-Coordinated Nanoassemblies Induce Cuproptosis in Canc

  2026-05-26

  This study introduces a baicalein–copper nanoassembly integrating chemodynamic and photodynamic modalities to induce cuproptosis—a copper-triggered form of cell death—for cancer therapy. The platform achieves efficient bone-penetration, selective tumor targeting, and robust generation of highly reactive oxygen species, providing a promising strategy for overcoming key limitations of current cancer treatments.

• MG-132 (Z-LLL-al): Precision Tools for Apoptosis and Cell Cy

  2026-05-26

  MG-132 (Z-LLL-al) stands out as a highly selective, cell-permeable proteasome inhibitor critical for dissecting apoptosis and cell cycle arrest mechanisms in cancer and neurobiology research. This guide delivers actionable workflows, troubleshooting insights, and data-driven context for maximizing experimental control with MG-132, as supported by advanced literature and the latest T-cell research.

• I-BET151 (GSK1210151A): Unlocking BET Inhibition for Disulfi

  2026-05-25

  Explore how I-BET151 (GSK1210151A) empowers advanced cancer research by targeting BET bromodomains, with a special focus on disulfidptosis and the super-enhancer landscape. This article uniquely bridges mechanistic insight with practical assay guidance for apoptosis and cell cycle arrest.

• ERK Signaling Drives IFNγ-Induced Apoptosis in Melanoma Cell

  2026-05-25

  Champhekar et al. reveal that ERK activation is essential for interferon gamma (IFNγ)-mediated cell death in melanoma. Their integrative genomic and functional analysis defines a mechanistic link between immune cytokine signaling and apoptosis, informing strategies for overcoming resistance in cancer immunotherapy.

• 2,5-di-tert-butylbenzene-1,4-diol: Precision in SERCA Inhibi

  2026-05-24

  2,5-di-tert-butylbenzene-1,4-diol (BHQ) offers researchers unparalleled control in calcium signaling and stem cell mobilization assays, leveraging selective SERCA inhibition. Grounded in recent mechanistic discoveries, BHQ empowers translational research by optimizing experimental reproducibility and providing novel directions for therapeutic applications.

• Balancing Self-Renewal and Differentiation in Human Intestin

  2026-05-23

  This study presents an optimized human intestinal organoid system that achieves a controlled balance between stem cell self-renewal and differentiation using small molecule pathway modulators. The approach enhances cellular diversity and proliferative capacity under a single culture condition, addressing a key challenge in organoid-based disease modeling and high-throughput screening.

• O-GlcNAcylation Rewires Glycolysis for Wnt-Driven Bone Forma

  2026-05-22

  This study uncovers how O-GlcNAcylation, a protein modification, is necessary for Wnt-stimulated bone formation by regulating aerobic glycolysis in osteoblasts. The findings reveal a metabolic mechanism linking Wnt signaling to bone anabolism, providing new avenues for skeletal and metabolic research.

• WP1066: Potent JAK2/STAT3 Inhibitor for Oncology and Regener

  2026-05-22

  WP1066 is a cell-permeable JAK2/STAT3 inhibitor that blocks phosphorylation and downstream signaling, showing efficacy in renal cell carcinoma and acute myeloid leukemia models. Its activity extends to inhibition of tumor angiogenesis and modulation of macrophage-driven bone regeneration pathways.

• 0.4% Trypan Blue Solution: Technical Guide for Cell Viabilit

  2026-05-21

  0.4% Trypan Blue Solution provides researchers with a straightforward, membrane-integrity-based method for live/dead cell discrimination and viability measurement in cell culture workflows. It is not intended for diagnostic or medical applications, and its reliability depends on correct handling and appropriate assay context.

• Optogenetic Control of Gene Therapy Using Light-Inducible RN

  2026-05-21

  The referenced study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that enables precise, reversible gene expression in vivo via light exposure. This innovation provides a compact, allosteric switch for translational control, offering new possibilities for timed and tissue-specific therapeutic interventions, particularly for metabolic and retinal diseases.

• Deferasirox (SKU A8639): Reliable Iron Chelation in Cancer R

  2026-05-20

  This article provides scenario-driven guidance for using Deferasirox (SKU A8639), an oral iron chelator, in cell viability and cancer research assays. Drawing on recent literature and practical workflow insights, it addresses common laboratory challenges—including iron chelation specificity, protocol optimization, and vendor selection—to help researchers achieve reproducible, high-quality results.

• IGF2BP3–FZD1/7 Axis Drives Stemness and Carboplatin Resistan

  2026-05-20

  This study reveals that IGF2BP3 stabilizes FZD1/7 mRNAs, enhancing cancer stem-like properties and resistance to carboplatin in triple-negative breast cancer (TNBC). The findings highlight a novel m6A-dependent regulatory mechanism, offering new targets to sensitize TNBC to platinum-based chemotherapy and improve treatment efficacy.

• AM 281: CB1 Cannabinoid Receptor Antagonist in TBI & Memory

  2026-05-19

  AM 281 stands out as a highly selective CB1 cannabinoid receptor antagonist for neuropharmacology, enabling precise modulation in cognitive dysfunction and traumatic brain injury models. Discover nuanced workflow strategies, troubleshooting insights, and direct applications informed by cutting-edge research on the CB1-CREB-GLT-1 axis.

11371 records 1/759 page Next 12345 下5页 Last page